| Patient | Pathological feature/size/location | Age (yr) | Sex | Next generation sequencing (MAF%) | BNA clamp | Sanger sequencing |
|---|---|---|---|---|---|---|
| 1 | Cavernous hemangioma (6.5 cm in greatest dimension), right lobe | 62 | Female | K-RAS p.G12D (0.75%) | Mutant | ND |
| 2 | Hemangioma of the liver (7.0 × 7.0 × 3.5 cm), left lateral lobe | 37 | Male | K-RAS p.G12S (0.1%)a; K-RAS p.G12D (0.1%) | Mutant | K-RAS p.G12S |
| 3 | Cavernous hemangioma (7 cm in greatest dimension), right lobe | 40 | Female | K-RAS p.G12S (0.2%) | Mutant | K-RAS p.G12S |
| 4 | Two hemangiomas (1.9 and 1.1 cm), right lobe | 57 | Male | K-RAS p.G13D (0.4%) K-RAS p.G13S (0.47%) | Mutant | ND |
| 5 | Cavernous hemangioma with scattered areas of sclerosis (6.3 cm), left lobe | 87 | Male | K-RAS p.G12D (0.68%) | Mutant | K-RAS p.G12C; K-RAS p.G12S |
| 6 | Cavernous hemangioma (10 cm) | 48 | Female | K-RAS p.G12S (0.31%) | Mutant | ND |
| 7 | Cavernous hemangioma with foci of necrosis and fibrosis (8.5 × 6 × 2 cm) | 43 | Female | K-RAS p.G12S (0.3%) BRAF p.V600M (0.17%)b | Mutant | K-RAS p.G12S; K-RAS p.G12D |
| 8 | Cavernous hemangioma of liver with extensive fibrosis, thrombi, and infarct (17.5 × 9 × 9 cm) | 48 | Male | K-RAS p.G12S (0.35%); K-RAS p.G12D (0.57%) K-RAS p.G13S (0.5%); K-RAS p.G13D (0.43%) | Mutant | K-RAS p.G12S; K-RAS p.G12V |
| 9 | Cavernous hemangioma (1.3 cm) | 50 | Female | K-RAS p.G12S (0.32%) | Mutant | ND |
| 10 | Cavernous hemangioma with focal degenerative change, segments 2 and 3 | 40 | Female | K-RAS p.G12S(0.25); K-RAS p.G13S (0.32%) | Mutant | ND |
| 11 | Cavernous hemangioma partially sclerosed (19.0 cm) | 42 | Male | K-RAS p.G13D (0.18%) | Mutant | K-RAS p.G12R |
| 12 | Cavernous hemangioma (1.5 cm), right lobe | 46 | Female | BRAF p.V600M (0.15%) | Mutant | BRAF p.V600M |
| 13 | Hemangioma (6.1 cm), left lobe | 55 | Female | BRAF p.V600M (0.2%) | Mutant | ND |
| 14 | Hepatic hemangioma (2.5 cm) | 42 | Female | BRAF p.V600M (0.18%) | Mutant | ND |
| Patient | Pathological feature/size/location | Age (yr) | Sex | Next generation sequencing (MAF%) | BNA clamp | Sanger sequencing |
|---|---|---|---|---|---|---|
| 1 | Cavernous hemangioma (6.5 cm in greatest dimension), right lobe | 62 | Female | K-RAS p.G12D (0.75%) | Mutant | ND |
| 2 | Hemangioma of the liver (7.0 × 7.0 × 3.5 cm), left lateral lobe | 37 | Male | K-RAS p.G12S (0.1%) | Mutant | K-RAS p.G12S |
| 3 | Cavernous hemangioma (7 cm in greatest dimension), right lobe | 40 | Female | K-RAS p.G12S (0.2%) | Mutant | K-RAS p.G12S |
| 4 | Two hemangiomas (1.9 and 1.1 cm), right lobe | 57 | Male | K-RAS p.G13D (0.4%) K-RAS p.G13S (0.47%) | Mutant | ND |
| 5 | Cavernous hemangioma with scattered areas of sclerosis (6.3 cm), left lobe | 87 | Male | K-RAS p.G12D (0.68%) | Mutant | K-RAS p.G12C; K-RAS p.G12S |
| 6 | Cavernous hemangioma (10 cm) | 48 | Female | K-RAS p.G12S (0.31%) | Mutant | ND |
| 7 | Cavernous hemangioma with foci of necrosis and fibrosis (8.5 × 6 × 2 cm) | 43 | Female | K-RAS p.G12S (0.3%) BRAF p.V600M (0.17%) | Mutant | K-RAS p.G12S; K-RAS p.G12D |
| 8 | Cavernous hemangioma of liver with extensive fibrosis, thrombi, and infarct (17.5 × 9 × 9 cm) | 48 | Male | K-RAS p.G12S (0.35%); K-RAS p.G12D (0.57%) K-RAS p.G13S (0.5%); K-RAS p.G13D (0.43%) | Mutant | K-RAS p.G12S; K-RAS p.G12V |
| 9 | Cavernous hemangioma (1.3 cm) | 50 | Female | K-RAS p.G12S (0.32%) | Mutant | ND |
| 10 | Cavernous hemangioma with focal degenerative change, segments 2 and 3 | 40 | Female | K-RAS p.G12S(0.25); K-RAS p.G13S (0.32%) | Mutant | ND |
| 11 | Cavernous hemangioma partially sclerosed (19.0 cm) | 42 | Male | K-RAS p.G13D (0.18%) | Mutant | K-RAS p.G12R |
| 12 | Cavernous hemangioma (1.5 cm), right lobe | 46 | Female | BRAF p.V600M (0.15%) | Mutant | BRAF p.V600M |
| 13 | Hemangioma (6.1 cm), left lobe | 55 | Female | BRAF p.V600M (0.2%) | Mutant | ND |
| 14 | Hepatic hemangioma (2.5 cm) | 42 | Female | BRAF p.V600M (0.18%) | Mutant | ND |
As a benefit of your subscription, you can share temporary access to restricted articles.
Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.
Please sign in to your personal account to gift article access.
As a benefit of your subscription, you can share temporary access to restricted articles.
Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.
Gift articles remaining: --
Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.
Gift articles remaining: --
As a benefit of your subscription, you can share temporary access to restricted articles.
Each link will stop working after 30 days or 10 uses.
You have reached the limit of 10 links within a 30 day period.
Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.